EL7.AI
StocksMediumUpdated•Originally published 30 September 2026•Updated 30 September 2026•
1 min read

Eli Lilly Study Shows Enhanced Weight Loss with New Zepbound Drug Combination

Key Facts

1A new study found that combining a next-generation Eli Lilly drug with Zepbound helped patients lose substantially more weight than Zepbound alone.
2The drug combination tested on people with Type 2 diabetes significantly lowered blood sugar levels.

A new study found that combining a next-generation Eli Lilly drug with Zepbound helped patients lose substantially more weight than Zepbound alone. The Wall Street Journal reported that the drug combination, tested on people with Type 2 diabetes, also significantly lowered blood sugar levels.

LLY closed at $1184.63 on September 29, 2026, prior to the release of study results evaluating the efficacy of combining different mechanisms of action to enhance obesity treatment outcomes. The positive clinical data supports the company's development of its weight-loss and diabetes drug pipeline.

Latest Updates · 1

  1. Notable·

    Update: Clinical trial results revealed that this drug combination achieved a 23% weight loss among participants. This specific percentage serves as a key indicator of the new treatment's efficacy compared to previous results achieved by the company's standalone medications.